相似文献
1
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x.
2
Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.
Leuk Lymphoma. 2019 May;60(5):1289-1293. doi: 10.1080/10428194.2018.1522437. Epub 2019 Jan 2.
3
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.
4
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
5
Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
Ann Hematol. 2014 May;93(5):797-802. doi: 10.1007/s00277-013-1989-5. Epub 2013 Dec 15.
6
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Clin Adv Hematol Oncol. 2009 May;7(5):334-42.
7
Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population.
Int J Lab Hematol. 2015 Aug;37(4):e91-5. doi: 10.1111/ijlh.12328. Epub 2015 Jan 28.
8
Prognostication in MF: from CBC to cytogenetics to molecular markers.
Best Pract Res Clin Haematol. 2014 Jun;27(2):155-64. doi: 10.1016/j.beha.2014.07.008. Epub 2014 Jul 18.
9
The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential thrombocythemia or primary myelofibrosis.
Leuk Lymphoma. 2016;57(1):209-11. doi: 10.3109/10428194.2015.1046065. Epub 2015 May 25.
10
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28.
引用本文的文献
1
Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.
J Clin Med. 2025 Feb 25;14(5):1537. doi: 10.3390/jcm14051537.
2
Topics of Interest in Women With Myeloproliferative Neoplasms.
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):74-87. doi: 10.1002/ajh.27665. Epub 2025 Mar 14.
3
Prognostic and Predictive Models in Myelofibrosis.
Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24.
4
Association between JAK2 variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms.
Ir J Med Sci. 2024 Dec;193(6):2883-2888. doi: 10.1007/s11845-024-03776-5. Epub 2024 Aug 14.
5
Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database.
Ann Hematol. 2024 Sep;103(9):3543-3551. doi: 10.1007/s00277-024-05894-7. Epub 2024 Jul 24.
6
Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.
Sci Rep. 2024 Apr 24;14(1):9389. doi: 10.1038/s41598-024-60090-x.
7
Incidence of blast phase in myelofibrosis according to anemia severity.
EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug.
8
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
Curr Hematol Malig Rep. 2022 Oct;17(5):127-139. doi: 10.1007/s11899-022-00672-6. Epub 2022 Sep 1.
9
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30.
10
Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Br J Haematol. 2021 Jun;193(6):1142-1150. doi: 10.1111/bjh.17534. Epub 2021 May 24.
本文引用的文献
1
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.
2
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients.
Leukemia. 2018 May;32(5):1254-1258. doi: 10.1038/s41375-018-0028-x. Epub 2018 Jan 30.
3
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.
4
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.
Am J Hematol. 2017 Nov;92(11):1193-1197. doi: 10.1002/ajh.24882. Epub 2017 Aug 28.
5
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
6
Why are hematopoietic stem cells so 'sexy'? on a search for developmental explanation.
Leukemia. 2017 Aug;31(8):1671-1677. doi: 10.1038/leu.2017.148. Epub 2017 May 15.
7
Update from the latest WHO classification of MPNs: a user's manual.
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542. doi: 10.1182/asheducation-2016.1.534.
8
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.
Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25.
9
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Br J Haematol. 2016 Aug;174(3):382-96. doi: 10.1111/bjh.14061. Epub 2016 Apr 7.
10
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11.
Zotero 插件